The IPO Buzz: Acrivon Therapeutics (ACRV) Launches $100.3 Million IPO

Acrivon Therapeutics (ACRV proposed), a cancer biotech, filed terms – 5.9 million shares at $16.00 to $18.00 – early today (Thursday, Nov. 3, 2022) and landed on next week’s IPO Calendar. The deal, which will raise $100.3 million if priced at the $17.00 mid-point, launched today as well. It’s set to price on Wednesday night, Nov. 9, to trade Thursday, Nov. 10, on the NASDAQ

Morgan Stanley, Jefferies, Cowen and Piper Sandler are the joint book-runners.

Patients with platinum-resistant ovarian, endometrial and bladder cancer will be treated in Phase 2 clinical trials of Acrivon Therapeutics’ leading drug candidate, ACR-368, according to the prospectus.

This is the first big IPO ($100 million-plus) to land on the IPO Calendar since Mobileye (MBLY) last week. Mobileye Global Inc., Intel’s self-driving car unit, raised $861 million – pricing its IPO at $21.00 – $1.00 above its range – on Tuesday night, Oct. 25. The stock jumped nearly 38 percent to close at $28.97 in its first day of NASDAQ trading on Wednesday, Oct. 26, 2022. Mobileye’s stock was trading at $24.86 at about 10:30 a.m. EDT on Thursday, Nov. 3.

Next week’s IPO Calendar now shows five deals – Acrivon Therapeutics and four micro-cap deals. More small deals, and possibly a SPAC IPO, may join the calendar in the next few days.

Stay tuned.

(For more information about these companies, please check the IPO Calendar and the individual IPO Profiles found on’s website.)

Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board. 

To see what time the NASDAQ IPOs are expected to trade, please log in to: then scroll down to IPO Message. 

Disclosure: Nobody on the staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The staff does not issue advice, recommendations or opinions.

Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums) is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. The SCOOP Rating does not reflect the opinions of anyone associated with The SCOOP ratings should not be taken as investment advice. The rating merely reflects the opinion of the professionals at the time of publication and is subject to last-minute changes due to market conditions, changes in a specific offering and other factors, such as changes in the proposed offering terms and the shifting of investor interest in the IPO. The information offered is taken from sources we believe to be reliable, but we cannot guarantee the accuracy.